Concepedia

C. R. Bradley

CR

Statistics

Publications

26

Citations

1.9K

H-Index

16

Active since

1989

Affiliations

Argonne National Laboratory(Current)

Texas Oncology

The McCrone Group (United States)

The University of Texas MD Anderson Cancer Center

C. R. Bradley is an author at Argonne National Laboratory specializing in oncology, medicine, and chemotherapy.

Publications per year

1989–2023

26

Publications

26

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

Joyce O’Shaughnessy, Cynthia Osborne, John Pippen et al. · New England Journal of Medicine · 2011 · 811 citations

, , +17

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial

Joyce O’Shaughnessy, Cynthia R. Osborne, John Pippen et al. · Journal of Clinical Oncology · 2009 · 243 citations

, , +17

Colloid Formation During Waste Form Reaction: Implications for Nuclear Waste Disposal

J.K. Bates, J. P. Bradley, Anna S Teetsov et al. · Science · 1992 · 144 citations

, , +17

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial

Joyce O’Shaughnessy, C. Osborne, John Pippen et al. · Journal of Clinical Oncology · 2009 · 94 citations

, , +17

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

David R. Fogelman, Robert A. Wolff, Scott Kopetz et al. · PubMed · 2011 · 93 citations

, , +17

1–5 of 26